Compare Bristol-Myers Squibb Co (BMY) vs Centene Corp (CNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Centene Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Centene Corp trades at $65.13 (market cap $32.05B). The key difference: Bristol-Myers Squibb Co is far larger — about 4.1× Centene Corp's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| BMY | CNC | |
|---|---|---|
Market Cap | $129.94B | $32.05B |
Sector | Health | Health |
52-Week High | $65.89 | $68.72 |
52-Week Low | $42.60 | $26.17 |
Enterprise Value | $163.92B | $21.10B |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →
